| Overall cohort (n = 14) . | |
|---|---|
| Any grade adverse events—no. (%) | 14 (100%) |
| Grade 3/4 adverse events—no. (%) | 6 (42.9) |
| Serious adverse events—no. (%) | 7 (50%) |
| Immune related adverse events—no. (%) | |
| Any grade | 2 (14.3%) |
| Grade 3/4 | 0 (0%) |
| Dose interruptions | 9 (64.3%) |
| Dose reductions to sitravatinib | 7 (50%) |
| Overall cohort (n = 14) . | |
|---|---|
| Any grade adverse events—no. (%) | 14 (100%) |
| Grade 3/4 adverse events—no. (%) | 6 (42.9) |
| Serious adverse events—no. (%) | 7 (50%) |
| Immune related adverse events—no. (%) | |
| Any grade | 2 (14.3%) |
| Grade 3/4 | 0 (0%) |
| Dose interruptions | 9 (64.3%) |
| Dose reductions to sitravatinib | 7 (50%) |
| Overall cohort (n = 14) . | |
|---|---|
| Any grade adverse events—no. (%) | 14 (100%) |
| Grade 3/4 adverse events—no. (%) | 6 (42.9) |
| Serious adverse events—no. (%) | 7 (50%) |
| Immune related adverse events—no. (%) | |
| Any grade | 2 (14.3%) |
| Grade 3/4 | 0 (0%) |
| Dose interruptions | 9 (64.3%) |
| Dose reductions to sitravatinib | 7 (50%) |
| Overall cohort (n = 14) . | |
|---|---|
| Any grade adverse events—no. (%) | 14 (100%) |
| Grade 3/4 adverse events—no. (%) | 6 (42.9) |
| Serious adverse events—no. (%) | 7 (50%) |
| Immune related adverse events—no. (%) | |
| Any grade | 2 (14.3%) |
| Grade 3/4 | 0 (0%) |
| Dose interruptions | 9 (64.3%) |
| Dose reductions to sitravatinib | 7 (50%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
